Chardan Capital Weighs in on Immunic FY2025 Earnings

Immunic, Inc. (NASDAQ:IMUX) – Equities researchers at Chardan Capital issued their FY2025 earnings estimates for shares of Immunic in a report issued on Wednesday, November 19th. Chardan Capital analyst K. Nakae anticipates that the company will post earnings of ($0.65) per share for the year. Chardan Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. Chardan Capital also issued estimates for Immunic’s FY2026 earnings at ($0.05) EPS.

A number of other research firms also recently issued reports on IMUX. Roth Capital initiated coverage on shares of Immunic in a research note on Friday, November 7th. They set a “buy” rating and a $3.00 price target on the stock. HC Wainwright reduced their target price on shares of Immunic from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, November 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Immunic in a research report on Wednesday, October 8th. D. Boral Capital dropped their price target on Immunic from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, November 13th. Finally, LADENBURG THALM/SH SH raised Immunic to a “strong-buy” rating in a research note on Thursday, October 16th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $7.40.

Immunic Stock Performance

NASDAQ IMUX opened at $0.71 on Monday. The stock has a 50 day moving average price of $0.82 and a 200-day moving average price of $0.84. Immunic has a one year low of $0.56 and a one year high of $1.42. The company has a market capitalization of $84.98 million, a P/E ratio of -0.75 and a beta of 1.53.

Immunic (NASDAQ:IMUX) last issued its earnings results on Thursday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.05.

Institutional Trading of Immunic

Several institutional investors and hedge funds have recently made changes to their positions in IMUX. Qube Research & Technologies Ltd bought a new position in shares of Immunic in the third quarter worth about $29,000. Millennium Management LLC lifted its holdings in Immunic by 414.5% during the 3rd quarter. Millennium Management LLC now owns 530,470 shares of the company’s stock valued at $468,000 after buying an additional 427,361 shares in the last quarter. Focus Partners Wealth boosted its position in Immunic by 1.5% in the 3rd quarter. Focus Partners Wealth now owns 2,581,587 shares of the company’s stock valued at $2,276,000 after buying an additional 39,063 shares during the period. Virtu Financial LLC bought a new position in Immunic in the 3rd quarter worth about $99,000. Finally, Two Sigma Investments LP purchased a new position in shares of Immunic during the third quarter worth approximately $52,000. 51.82% of the stock is currently owned by institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.